KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Total Liabilities (2016 - 2025)

Historic Total Liabilities for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to $216.3 million.

  • Nektar Therapeutics' Total Liabilities fell 1652.8% to $216.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.3 million, marking a year-over-year decrease of 1652.8%. This contributed to the annual value of $243.1 million for FY2024, which is 896.21% down from last year.
  • Nektar Therapeutics' Total Liabilities amounted to $216.3 million in Q3 2025, which was down 1652.8% from $231.7 million recorded in Q2 2025.
  • Nektar Therapeutics' 5-year Total Liabilities high stood at $475.7 million for Q3 2021, and its period low was $216.3 million during Q3 2025.
  • In the last 5 years, Nektar Therapeutics' Total Liabilities had a median value of $297.3 million in 2023 and averaged $329.9 million.
  • Its Total Liabilities has fluctuated over the past 5 years, first surged by 4087.18% in 2021, then plummeted by 2626.97% in 2023.
  • Nektar Therapeutics' Total Liabilities (Quarter) stood at $437.7 million in 2021, then dropped by 21.41% to $344.0 million in 2022, then fell by 22.36% to $267.0 million in 2023, then dropped by 8.96% to $243.1 million in 2024, then decreased by 11.05% to $216.3 million in 2025.
  • Its Total Liabilities stands at $216.3 million for Q3 2025, versus $231.7 million for Q2 2025 and $242.5 million for Q1 2025.